证券研究报告 | 2026年02月26日 2026年02月27日 策略月报 一页纸精读行业比较数据：2 月 投资链：2 月以来有色价格全面上升。25 年 12 月固定资产投资累计同比增 速下降至-3.80%，房地产开发投资累计同比降幅下降至-17.20%，制造业固 定资产投资累计同比增速下降至 0.60%，基础设施建设投资累计同比增速下 降至-1.48%。26 年 2 月以来铜、铝、锌、铅、锡、镍、黄金、白银价格上升； 26 年 2 月动力煤价格持平于 685 元/吨，焦煤价格持平；26 年 2 月普通水泥 平均价格下降；26 年 2 月以来钢材价格下降；26 年 2 月以来轻质纯碱价格 下降；26 年 1 月大型、轻型客车销量当月同比增速下降，中型客车当月同比 增速上升。 消费链：1 月汽车销量同比增速小幅回升。2025 年 12 月社消额当月名义同 比增速回落至 0.90%，累计名义同比增速回落 3.70%；25 年 12 月消费者信心 指数下降至 89.50；2025 年 12 月商品房销售面积累计同比增速降幅扩大， 增速下降至-9.53%；2026 年 1 月汽车销量当月同比增速上升至-3.18%；2 ...

Investment Chain - Non-ferrous metal prices have risen since February 2026, with fixed asset investment growth in December 2025 declining to -3.80%[1] - Real estate development investment in December 2025 saw a year-on-year decline of 17.20%[1] - Manufacturing fixed asset investment growth in December 2025 decreased to 0.60%[1] - Infrastructure investment growth in December 2025 fell to -1.48%[1] Consumption Chain - In December 2025, the nominal year-on-year growth rate of social consumption fell to 0.90%, with a cumulative decline of 3.70%[2] - The consumer confidence index in December 2025 dropped to 89.50[2] - In January 2026, automobile sales saw a year-on-year growth rate increase to -3.18%[2] - Home appliance retail sales in December 2025 experienced a year-on-year decline of 14.25%[2] Export Chain - In December 2025, exports to Japan and ASEAN saw a year-on-year growth increase, while exports to the US and EU declined[3] - The export growth rate for electronic products in December 2025 rose to 37.25%[3] - Textile export value in December 2025 decreased by 4.23% year-on-year[3] - Mechanical export value in December 2025 increased by 6.60% year-on-year[3] Price Chain - As of February 2026, the price of pork decreased to 12.75 yuan/kg[4] - WTI crude oil price increased to $65.63 per barrel on February 24, 2026[4] - PVC spot price rose to 4770 yuan/ton on February 24, 2026[4] - The average price of coal in Qinhuangdao increased in February 2026[4]

Core Viewpoint - The penicillin industry in China is undergoing structural adjustment and high-quality development, with a complete industrial chain from raw material supply to end application, and is expected to maintain steady growth driven by increasing demand from grassroots healthcare and an aging population [1][12]. Industry Overview - Penicillin is a β-lactam antibiotic that disrupts bacterial cell walls and is crucial in treating bacterial infections, significantly impacting human health since its discovery [1][12]. - The Chinese penicillin industry has established a mature industrial chain and occupies a significant position in the global intermediate market [1][12]. - The market size of the Chinese penicillin industry is projected to reach 28.243 billion yuan in 2024, with a year-on-year growth of 4.45% [1][12]. Industry Development History - Penicillin was the first broad-spectrum antibiotic discovered, significantly increasing human lifespan and saving millions during World War II [7]. - China began domestic production of penicillin in the early 1950s, achieving self-sufficiency and eventually becoming the world's largest producer by 2001 [7]. Industry Chain - The penicillin industry chain consists of upstream raw material suppliers and strain research institutions, midstream penicillin producers and intermediate manufacturers, and downstream sales channels including pharmaceutical distributors and e-commerce platforms [8][10]. Current Industry Status - The antibiotic industry in China is primarily focused on generic drug production, with limited innovative drug development [10][11]. - The market size of the antibiotic industry is expected to grow from 153.384 billion yuan in 2016 to 217.251 billion yuan in 2024, with a compound annual growth rate of 4.45% [10][11]. Competitive Landscape - The Chinese penicillin industry features a mix of domestic and foreign companies, with domestic firms like North China Pharmaceutical and Shijiazhuang Pharmaceutical Group gradually replacing foreign products in the mid to low-end market [13][14]. Key Companies - North China Pharmaceutical Co., Ltd. is a leading player in the antibiotic sector, with a comprehensive product line covering raw materials to formulations, and reported a revenue of 2.251 billion yuan in chemical preparations for the first half of 2025, a decrease of 6.36% year-on-year [15][16]. - Shandong Lukang Pharmaceutical Co., Ltd. focuses on a diverse range of pharmaceutical products and reported a revenue of 3.384 billion yuan for human medicines in 2024, reflecting a growth of 5.16% [16]. Industry Development Trends - Future research and development in penicillin will focus on innovative drug design to combat antibiotic resistance and enhance clinical efficacy [17]. - Clinical applications of penicillin are shifting towards precision medicine, utilizing advanced diagnostic techniques for optimal drug selection [18]. - Production processes are expected to transition to more efficient and environmentally friendly methods, enhancing productivity and reducing waste [20]. - Quality standards in the penicillin industry will evolve to encompass comprehensive lifecycle management, ensuring high safety and efficacy [21].

Group 1 - Penicillin was the most effective antibacterial drug during the war, but its production began only after World War II, with China being one of the first countries to develop penicillin independently [1][12] - The first large-scale industrial production of penicillin in China started in 1953 at the Shanghai Third Pharmaceutical Factory, breaking the foreign monopoly [1][48] - The initial strain of penicillin used in China came from a mold found on an old pair of shoes, showcasing the resourcefulness of Chinese scientists during wartime [1][19][20] Group 2 - The development of penicillin in China faced numerous challenges, including a lack of equipment and funding, especially during the war and post-war periods [1][15][39] - The production process was complicated by the need for specific growth conditions for the penicillin mold, which required innovative solutions from the research team [1][24][40] - By 1953, the Shanghai Third Pharmaceutical Factory achieved industrial-scale production, marking a significant milestone in China's pharmaceutical industry [1][46][48] Group 3 - The historical context of penicillin's development highlights the importance of scientific collaboration and innovation in overcoming resource limitations [1][22][25] - The transition from penicillin being a rare and expensive drug to a widely available treatment illustrates the advancements in China's pharmaceutical capabilities [1][50] - The establishment of the Shanghai Third Pharmaceutical Factory laid the foundation for China's antibiotic production and contributed to the training of thousands of professionals in the field [1][48][50]

Core Viewpoint - The article emphasizes China's dominant position in the global pharmaceutical supply chain, particularly in the production of Active Pharmaceutical Ingredients (APIs) and Key Starting Materials (KSMs), which poses a significant asymmetric threat to U.S. national security [4][5]. Group 1: China's Dominance in Pharmaceutical Supply Chain - China holds a near-monopoly in the production of various pharmaceutical raw materials, with over 90% of global antibiotic intermediates supplied by China [18]. - Approximately 70%-80% of global vitamin production capacity is controlled by China, making it a critical player in the pharmaceutical industry [19]. - China's low-cost, high-output chemical manufacturing capabilities create significant barriers for competitors, allowing it to define prices and capacities in the market [21]. Group 2: Impact of Geopolitical Tensions - The U.S.-China trade tensions have led to concerns about the dependency of the U.S. on Chinese pharmaceutical supplies, which could lead to drug shortages in critical situations [9][10]. - The article illustrates a hypothetical scenario where geopolitical tensions could disrupt the supply of essential medications, highlighting the risks of "asymmetric interdependence" [7][9]. - The ongoing drug shortage issues in the U.S. are exacerbated by the complex global supply chain, where many active ingredients are sourced from China [10][11]. Group 3: Historical Context and Strategic Decisions - The article discusses the historical context of the pharmaceutical industry's shift, where Western companies outsourced low-margin API production to lower-cost countries, primarily China, while retaining high-margin R&D and marketing functions [23][24]. - This outsourcing has led to a significant loss of industrial capability in the West, as the foundational skills and infrastructure for API production have diminished [32]. Group 4: Challenges for India as an Alternative - India, often referred to as the "world's pharmacy," lacks the complete supply chain necessary for API production, relying heavily on Chinese intermediates [36][38]. - Despite efforts to establish a domestic API supply chain, India's progress is hindered by infrastructure challenges and the dominance of Chinese suppliers [37][39]. Group 5: Future Outlook and Strategic Recommendations - The article suggests that China is transitioning from merely being a low-cost producer to becoming a leader in technology and standards within the pharmaceutical industry [43]. - As geopolitical tensions rise, the need for China to innovate in green technologies and maintain its competitive edge in the pharmaceutical supply chain becomes critical [55][56]. - The future of the pharmaceutical industry will focus on balancing efficiency and safety, with the ability to provide cost-effective and safe drugs being a key determinant of success [58].

Core Viewpoint - The article emphasizes China's dominant position in the global pharmaceutical supply chain, particularly in the production of Active Pharmaceutical Ingredients (APIs) and Key Starting Materials (KSMs), which poses a significant asymmetric threat to U.S. national security [3][4][10]. Group 1: China's Dominance in Pharmaceutical Supply Chain - China holds a near-monopoly in several key areas of pharmaceutical production, including over 90% of global antibiotic intermediates and 70%-80% of vitamin production capacity [13][10]. - The U.S. and Europe dominate patented and biological drugs, while India is known as the "world's pharmacy" for its large-scale production of generic drugs, but it relies heavily on China for approximately 70% of its active ingredients and intermediates [10][22]. - The integration of China's chemical industry has created significant cost advantages, with production costs being 30%-40% lower than those in Europe and the U.S., and even 20% lower than in India [15][18]. Group 2: Implications of Supply Chain Dependency - The U.S. faces a critical dependency on Chinese pharmaceutical supplies, which could lead to severe shortages in essential medications, as highlighted by potential disruptions in supply chains due to geopolitical tensions [4][6]. - The FDA's reports indicate ongoing drug shortages in the U.S., exacerbated by the complex and often misleading nature of pharmaceutical supply chains, where active ingredients may originate from various countries, including China [6][7]. - The article warns that the "asymmetric interdependence" between the U.S. and China in the pharmaceutical sector could lead to significant vulnerabilities for the U.S. healthcare system [4][6]. Group 3: Future Outlook and Strategic Considerations - As the U.S. pushes for decoupling from China, the article suggests that rebuilding a lost industrial base in pharmaceuticals will be a long and challenging process, requiring a new generation of skilled engineers and a cultural shift towards accepting chemical manufacturing [29][30]. - The article posits that while China currently holds a strategic advantage, it must remain vigilant against emerging technologies in biomanufacturing that could disrupt its dominance [30]. - The future of the pharmaceutical industry will hinge on balancing efficiency and safety, with the ability to provide lower-cost, safer drugs being a key competitive factor [31].

Core Viewpoint - The article highlights the significant contributions of Chinese scientists and academic institutions during the Anti-Japanese War, emphasizing their resilience and innovation in the face of adversity, as documented in the book "Rise: Science and Scientists during the War" [3][7][11]. Group 1: Contributions of Scientists - Chinese scientists engaged in various research projects to support wartime needs, such as extracting oil from castor seeds and developing nutritional improvements for soldiers [4][9]. - Notable figures like Wu Da You and Hua Luo Geng continued their research under challenging conditions, showcasing their dedication to science [4][9]. - The establishment of research institutions in safer regions, such as Kunming and Chongqing, allowed for continued scientific work despite the war [8][10]. Group 2: Challenges Faced - The war led to the destruction of many universities and research facilities, forcing scientists to relocate and adapt to new environments [8][9]. - The article describes the harsh conditions under which scientists operated, often lacking basic resources like electricity and water [5][11]. - The impact of the war on scientific progress was profound, yet it also spurred innovation and collaboration among scientists [7][11]. Group 3: International Collaboration - Foreign experts, including medical personnel, came to China to assist in wartime efforts, fostering international scientific cooperation [11][12]. - The efforts of scientists during this period not only contributed to the war effort but also laid the groundwork for future scientific advancements in China [11][12]. - The book illustrates how these collaborations helped bridge the gap between Eastern and Western scientific communities during a time of crisis [12].

邓叔群院士在战火纷飞的年代，为保护珍贵菌物标本，辗转将其送往美国康奈尔大学暂存，如今这些标 本随祖国实力提升无偿回归，成为学科发展与国家强盛的见证；魏江春院士则以"极地探险家"的姿态， 克服青藏高原缺氧、南极冰原严寒等极端环境开展科考，九十高龄仍亲赴沙漠推动沙漠生物地毯工程， 用行动诠释"持续探索"的科学精神。 郑儒永、庄文颖两位女科学家的故事同样令人感动。郑儒永院士将毕生积蓄150万元捐赠设立"郑儒永黄 河奖学金"，助力青年科研人员成长；庄文颖院士46年专注真菌分类研究，足迹遍布26个省份采集样 品，主编《中国真菌志》，坚守"中国真菌学要掌握在自己人手中"的信念。这些故事向同学们生动展现 了科学家们爱国奉献、淡泊名利、潜心钻研的精神底色。 齐莎在讲座中提到，全球约有220万—380万种真菌，目前被描述的仅15万种左右，仍有大量未知领域等 待探索。她呼吁更多人关注真菌学研究，传承先驱者的科学精神，在未知世界中持续开拓。 作为2025年弘扬科学家精神系列活动之一，本次活动由北京市科技教育中心（北京市科学技术协会党 校）在北京市科学技术协会的指导下，联合北京市东城区科学技术协会共同开展，活动得到北京市崇文 小学的 ...

Core Viewpoint - Chuaning Bio announced a gradual decline in penicillin product prices and that the price of 6-APA is currently at historical lows, indicating a challenging pricing environment for the company [2] Pricing Summary - The price of penicillin products is gradually decreasing, while 6-APA prices are fluctuating at historical low levels [2] Cost Summary - The cost in the first three quarters showed little fluctuation compared to the first half of the year, with the primary impact on gross profit margin stemming from price volatility [2] Future Outlook - With the arrival of the peak season in the fourth quarter and an increase in downstream market demand, the company expects a recovery in gross margin [2]

Group 1: Market Performance and Product Pricing - The price of erythromycin thiocyanate has remained stable, consistent with the same period last year, due to stable market demand and supply in 2024 [2] - The prices of 6-APA and industrial salt for penicillin products have returned to near five-year historical lows, with expectations for a price rebound as outdated production capacity is phased out [3] - The overall price of cephalosporin products has shown minor fluctuations since the beginning of the year, with future adjustments based on market demand and production capacity [4] Group 2: AI Applications in Production - AI-controlled fermentation tanks have shown a 3%-5% increase in yield compared to traditional methods, with ongoing data iterations expected to further enhance production efficiency [3] - The AI system can predict fermentation trends in real-time, allowing for proactive adjustments to maintain production stability and reduce fluctuations [3] Group 3: Revenue and Order Projections - Revenue from synthetic biology products reached CNY 48.8 million in the first three quarters of 2025, with improved order conditions compared to the same period last year [4] - Future revenue is expected to significantly improve as production capacity increases and market expansion continues [4] Group 4: Cost and Expense Management - Overall expenses increased by 26% year-on-year in the first three quarters of 2025, primarily due to R&D costs associated with new product development [6] - Anticipated cost reductions in the fourth quarter due to the absence of one-time expenses and decreasing trial production costs [6] Group 5: Raw Material and Energy Costs - The price of corn, a primary raw material, is projected to be CNY 1.9-2.0 per kg (excluding tax), reflecting an increase compared to last year [6] - Energy costs, primarily from coal, are expected to remain stable over the next two years despite regional influences [6] Group 6: Profit Margin Trends - The overall gross margin for the first three quarters of 2025 was 32.8%, a decrease of 3.1% compared to the first half of the year, influenced by price and cost fluctuations [7] - Anticipated recovery in gross margins in the fourth quarter due to increased market demand during the peak season [8]